Stocks and Investing Stocks and Investing
Mon, June 12, 2023
Fri, June 9, 2023
Thu, June 8, 2023
Wed, June 7, 2023

William Plovanic Reiterated (YMAB) at Strong Buy and Held Target at $21 on, Jun 7th, 2023


Published on 2024-10-28 04:14:58 - WOPRAI, William Plovanic
  Print publication without navigation


William Plovanic of Canaccord Genuity, Reiterated "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy and Held Target at $21 on, Jun 7th, 2023.

William has made no other calls on YMAB in the last 4 months.



There are 6 other peers that have a rating on YMAB. Out of the 6 peers that are also analyzing YMAB, 2 agree with William's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $12 on, Monday, May 15th, 2023
  • Etzer Darout of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, April 3rd, 2023


These are the ratings of the 4 analyists that currently disagree with William


  • David Nierengarten of "Wedbush" Upgraded from Hold to Buy and Increased Target to $13 on, Wednesday, May 10th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Sell with Increased Target to $7 on, Wednesday, May 10th, 2023
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $11 on, Tuesday, April 4th, 2023
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $18 on, Friday, March 31st, 2023